Scriptaid targets HDAC1, 2, and 8, and HDAC6 of Class IIb and has been developed as a potent HDACi with anti-tumour activity against several cancers such as endometrial, ovarian, colon or lung cancer [32,40]. This evidence concerns the gene HDAC1 and neoplasm.